Anam Rubbab Pasha, Saeed Ullah, Sobia Ahsan Halim, Ajmal Khan, Javid Hussain, El-kott Attalla F., Muhammad Moazzam Naseer, Waleed Eltantawy, Ahmed Al-Harrasi and Zahid Shafiq* Pages 1 - 12 ( 12 )
Introduction: Prolyl-specific oligopeptidase (POP), one of the brain's highly expressed enzymes, is an important target for the therapy of central nervous system disorders, notably autism spectrum disorder, schizophrenia, Parkinson's, Alzheimer's disease, and dementia.
Method: The current study was designed to investigate 2,4-bis(trifluoromethyl) benzaldehyde- based thiosemicarbazones as POP inhibitors to treat the above-mentioned disorders. A variety of techniques, such as nuclear magnetic resonance (NMR), mass spectrometry (MS), and Fourier-transform infrared spectroscopy (FTIR), were used for the structural confirmation of synthesized compounds. After in-vitro evaluation, all of these compounds were found to be prominent inhibitors of the POP enzyme (IC50= 10.14 - 41.73 μM).
Result: Compound 3a emerged as the most active compound (IC50 10.14 ± 0.72 μM) of the series. The kinetic study of the most active 3a (Ki =13.66 0.0012 μM) indicated competitive inhibition of the aforementioned enzyme.
Conclusion: Moreover, molecular docking depicted a noticeable role of thiosemicarbazide moiety in the binding of these molecules within the active site of the POP enzyme.
2,4-Bis(trifluoromethyl)benzaldehyde, thiosemicarbazone, prolyl endo-peptidase inhibitors, molecular docking, kinetics.